Canadian consensus: a new systemic treatment algorithm for advanced EGFR-mutated non-small-cell lung cancer

Area of Science:

• Oncology
• Medical Genetics
• Clinical Therapeutics

Background:

• Recent clinical trials have significantly altered the treatment landscape for advanced EGFR-mutated non-small-cell lung cancer (NSCLC).
• Key clinical questions have emerged regarding optimal sequencing and treatment strategies for various patient subgroups.
• The management of NSCLC with uncommon EGFR mutations remains an area requiring further evidence.

Purpose of the Study:

• To address critical clinical questions in the management of advanced EGFR-mutated NSCLC.
• To review and synthesize recent evidence on treatment efficacy and sequencing.
• To establish expert consensus recommendations and an updated treatment algorithm.

Main Methods:

• Convening a Canadian expert panel.
• Defining key clinical questions for advanced EGFR-mutated NSCLC.
• Reviewing recent clinical trial evidence and discussing practice recommendations.

Main Results:

• Osimertinib is the preferred first-line treatment for common EGFR mutations, including those with brain metastasis, due to overall survival and CNS activity.
• Subsequent line treatment decisions are based on first-line therapy and T790M mutation status.
• Evidence for treating uncommon EGFR mutations is primarily derived from retrospective and limited prospective studies.

Conclusions:

• Significant advances in EGFR-mutated NSCLC treatment have necessitated updated expert consensus and treatment algorithms.
• Osimertinib has emerged as a preferred first-line option for common EGFR mutations.
• Further research is needed to clarify optimal treatment strategies for uncommon EGFR mutations and in later lines of therapy.